Sodium-glucose co-transporter 2 (SGLT2) Inhibitors: New Target for Type 2 Diabetes Mellitus (T2DM) Review

Knocking out type2 diabetes by new insulin independent renal glucose transporters as targets, reducing the side effects related to high rise in glucose levels is a more efficient way to manage diabetes. Sodium-glucose co-transporter 2 (SGLT2) inhibitors block reabsorptionof glucose back into the blood and stimulate secretion in urine in a way controlling blood glucose levels. Areas discussed: We emphasize in this review an overview of type 2 diabetes. New insulin independent targets, SGLT family inhibitors and their mechanism of action are briefly discussed. Molecular modeling studies carried out for new analogues of SGLT2 were indicated and also about current marketed SGLT drugs their safety issues are briefly outlined. Conclusion: SGLT2 inhibitors are very promising drugs for near future, where insulin sensitization is a problem. A combination of drugs related to insulin dependent pathway and also independent pathway like SGLT2/SGLT1 drugs will be more effective in glycemic control with lesser side effects.
Diabetes, Blood Sugar, Diabetic, Medicine, Insulin

Comments

Popular posts from this blog

Synthesis Characterization and Evaluation of Novel Substituted Azole Derivatives

Separation and Identification of the Components of Acacia Sieberiana Stem Bark Plant Extract and Study its Safety as a Treatment Drug for Diarrhea

Reuse of Treated Wastewater of the City of Salé in Agriculture